NeuroSense Therapeutics (NRSNW) Competitors $0.42 -0.08 (-16.28%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends NRSNW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ALVO, ACABW, ACABU, BFRIW, and BTMDWShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Alvotech (ALVO), Atlantic Coastal Acquisition Corp. II (ACABW), Atlantic Coastal Acquisition Corp. II (ACABU), Biofrontera (BFRIW), and biote (BTMDW). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Alvotech Atlantic Coastal Acquisition Corp. II Atlantic Coastal Acquisition Corp. II Biofrontera biote NeuroSense Therapeutics (NASDAQ:NRSNW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Which has preferable earnings & valuation, NRSNW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the MarketBeat Community prefer NRSNW or ATNFW? NeuroSense Therapeutics and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformNeuroSense TherapeuticsN/AN/A180 Life SciencesN/AN/A Is NRSNW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer NRSNW or ATNFW? In the previous week, NeuroSense Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment NeuroSense Therapeutics Neutral 180 Life Sciences Neutral SummaryNeuroSense Therapeutics and 180 Life Sciences tied by winning 0 of the 0 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSNW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSNW vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$165.68M$5.14B$9.08BDividend YieldN/A3.64%5.09%4.23%P/E RatioN/A115.5190.0517.18Price / SalesN/A18,531.021,116.25117.05Price / CashN/A12.8743.1037.85Price / BookN/A8.594.784.78Net IncomeN/A-$20.67M$120.31M$225.60M7 Day Performance67.44%-1.05%-1.92%-1.23%1 Month Performance179.07%174.77%13.65%0.46%1 Year Performance222.00%134.18%28.34%15.24% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNWNeuroSense TherapeuticsN/A$0.42-16.3%N/A+222.7%$0.00N/A0.0010Gap DownATNFW180 Life SciencesN/A$0.01flatN/A+31.6%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/A$0.04-25.7%N/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.16+6.2%N/A+22.1%$0.00N/A0.002AIMDWAinosN/A$0.03flatN/A-89.6%$0.00$40,633.000.0040News CoverageGap UpALVOWAlvotechN/A$2.78+1.1%N/A+48.5%$0.00$391.87M0.004Gap UpALVOAlvotech2.6676 of 5 stars$12.05+2.1%$18.00+49.4%+6.9%$0.00$93.38M0.001,026ACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/A+408.0%$0.00N/A0.004ACABUAtlantic Coastal Acquisition Corp. IIN/A$8.05-26.8%N/AN/A$0.00N/A0.004Gap DownBFRIWBiofronteraN/A$0.09-0.1%N/A+340.0%$0.00$35.36M0.0070Positive NewsBTMDWbioteN/A$0.47flatN/A-56.1%$0.00$193.06M0.00N/A Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ALVO Competitors ACABW Competitors ACABU Competitors BFRIW Competitors BTMDW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRSNW) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSNW Stock Alerts